Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function

  1. Ravi Vijayvargia
  2. Raquel Epand
  3. Alexander Leitner
  4. Tae-Yang Jung
  5. Baehyun Shin
  6. Roy Jung
  7. Alejandro Lloret
  8. Randy Singh Atwal
  9. Hyeongseok Lee
  10. Jong-Min Lee
  11. Ruedi Aebersold
  12. Hans Hebert
  13. Ji-Joon Song
  14. Ihn Sik Seong  Is a corresponding author
  1. The Maharaja Sayajirao University of Baroda, India
  2. McMaster University, Canada
  3. Eidgenössische Technische Hochschule Zürich, Switzerland
  4. Korea Advanced Institute of Science and Technology, Republic of Korea
  5. Massachusetts General Hospital, United States
  6. Universidad Autónoma de Querétaro, Mexico
  7. Karolinska Institute, Sweden

Abstract

The polyglutamine expansion in huntingtin protein causes Huntington's disease. Here, we investigated structural and biochemical properties of huntingtin and the effect of the polyglutamine expansion using various biophysical experiments including circular dichroism, single-particle electron microscopy and cross-linking mass spectrometry. Huntingtin is likely composed of five distinct domains and adopts a spherical α-helical solenoid where the amino-terminal and carboxyl-terminal regions fold to contain a circumscribed central cavity. Interestingly we showed that the polyglutamine expansion increases α-helical properties of huntingtin and affects the intramolecular interactions among the domains. Our work delineates the structural characteristics of full-length huntingtin, which are affected by the polyglutamine expansion, and provides an elegant solution to the apparent conundrum of how the extreme amino-terminal polyglutamine tract confers a novel property on huntingtin, causing the disease.

Article and author information

Author details

  1. Ravi Vijayvargia

    Department of Biochemistry, The Maharaja Sayajirao University of Baroda, Vadodara, India
    Competing interests
    The authors declare that no competing interests exist.
  2. Raquel Epand

    Biochemical ad Biomedical Sciences, McMaster University, Hamilton, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Alexander Leitner

    Department of Biology, Institute of Molecular Systems Biology, Eidgenössische Technische Hochschule Zürich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Tae-Yang Jung

    Department of Biological Sciences, Cancer Metastasis Control Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  5. Baehyun Shin

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Roy Jung

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Alejandro Lloret

    Facultad de Medicina, Universidad Autónoma de Querétaro, Santiago de Querétaro, Mexico
    Competing interests
    The authors declare that no competing interests exist.
  8. Randy Singh Atwal

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Hyeongseok Lee

    Department of Biological Sciences, Cancer Metastasis Control Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  10. Jong-Min Lee

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ruedi Aebersold

    Department of Biology, Institute of Molecular Systems Biology, Eidgenössische Technische Hochschule Zürich, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  12. Hans Hebert

    Department of Biosciences and Nutrition, Karolinska Institute, Solna, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  13. Ji-Joon Song

    Department of Biological Sciences, Cancer Metastasis Control Center, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
    Competing interests
    The authors declare that no competing interests exist.
  14. Ihn Sik Seong

    Center for Human Genetic Research, Massachusetts General Hospital, Boston, United States
    For correspondence
    iseong@mgh.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Vijayvargia et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,738
    views
  • 973
    downloads
  • 53
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ravi Vijayvargia
  2. Raquel Epand
  3. Alexander Leitner
  4. Tae-Yang Jung
  5. Baehyun Shin
  6. Roy Jung
  7. Alejandro Lloret
  8. Randy Singh Atwal
  9. Hyeongseok Lee
  10. Jong-Min Lee
  11. Ruedi Aebersold
  12. Hans Hebert
  13. Ji-Joon Song
  14. Ihn Sik Seong
(2016)
Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function
eLife 5:e11184.
https://doi.org/10.7554/eLife.11184

Share this article

https://doi.org/10.7554/eLife.11184

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics
    Elise S Bruguera, Jacob P Mahoney, William I Weis
    Research Article

    Wnt/β-catenin signaling directs animal development and tissue renewal in a tightly controlled, cell- and tissue-specific manner. In the mammalian central nervous system, the atypical ligand Norrin controls angiogenesis and maintenance of the blood-brain barrier and blood-retina barrier through the Wnt/β-catenin pathway. Like Wnt, Norrin activates signaling by binding and heterodimerizing the receptors Frizzled (Fzd) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), leading to membrane recruitment of the intracellular transducer Dishevelled (Dvl) and ultimately stabilizing the transcriptional coactivator β-catenin. Unlike Wnt, the cystine knot ligand Norrin only signals through Fzd4 and additionally requires the co-receptor Tetraspanin12 (Tspan12); however, the mechanism underlying Tspan12-mediated signal enhancement is unclear. It has been proposed that Tspan12 integrates into the Norrin-Fzd4 complex to enhance Norrin-Fzd4 affinity or otherwise allosterically modulate Fzd4 signaling. Here, we measure direct, high-affinity binding between purified Norrin and Tspan12 in a lipid environment and use AlphaFold models to interrogate this interaction interface. We find that Tspan12 and Fzd4 can simultaneously bind Norrin and that a pre-formed Tspan12/Fzd4 heterodimer, as well as cells co-expressing Tspan12 and Fzd4, more efficiently capture low concentrations of Norrin than Fzd4 alone. We also show that Tspan12 competes with both heparan sulfate proteoglycans and LRP6 for Norrin binding and that Tspan12 does not impact Fzd4-Dvl affinity in the presence or absence of Norrin. Our findings suggest that Tspan12 does not allosterically enhance Fzd4 binding to Norrin or Dvl, but instead functions to directly capture Norrin upstream of signaling.